Metabolically activated recombinant viral vectors and methods for their preparation and use

• US 8,093,054 B2
• Filed: 10/22/2010
• Issued: 01/10/2012
• Est. Priority Date: 08/09/1999
• Status: Expired due to Fees

• Current Assignee: Genzyme Corporation (Sanofi )
• Original Assignee: Genzyme Corporation (Sanofi )
• Inventors: Carter, Barrie J.
• Primary Examiner(s): Pneg, Bo
• Application Number:
  US12/910,711
• Publication Number:
  US 20110104117A1
• Time in Patent Office: 445 Days
• Field of Search: None
• US Class Current: 435/456
• CPC Class Codes: A61K 38/191 Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: C07K 14/70578 NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 NGF-receptor C07K14/71, TNF-receptor C07K14/7151
• CPC Class Codes: C07K 16/00 Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies antibodies with enzymatic activity, e.g. abzymes C12N9/0002
• CPC Class Codes: C07K 2319/30 Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
• CPC Class Codes: C07K 2319/33 fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
• CPC Class Codes: C12N 15/86 Viral vectors
• CPC Class Codes: C12N 2750/14143 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12P 21/06 produced by the hydrolysis of a peptide bond, e.g. hydrolysate products preparing foodstuffs by protein hydrolysis A23J3/00

Abstract

Recombinant viral vectors, especially parvovirus vectors such as adeno-associated virus (AAV) vectors; capable of enhanced expression of heterologous sequences, and methods for their construction and use, are provided. The vectors have a structure, or are capable of rapidly adopting a structure, which involves intrastrand base pairing of at least one region in a heterologous sequence.

Claims

1. A composition comprising a purified recombinant adeno-associated virus (rAAV) particle comprising an AAV capsid and a single-stranded rAAV vector genome, wherein the rAAV vector genome comprises in the 5′

to 3′

direction;

a 5′

AAV inverted terminal repeat (ITR) sequence, a first heterologous nucleotide sequence, an internal AAV ITR sequence, a second heterologous nucleotide sequence, and a 3′

AAV ITR sequence, wherein the first heterologous nucleotide sequence can form intrastrand base pairs with the second nucleotide sequence along most or all of its length.

2. The composition of claim 1, wherein the composition is essentially free of helper virus.

3. The composition of claim 1, wherein the vector genome has a size of about 4.5 kilobase to about 5.2 kilobase.

4. The composition of claim 1, wherein the internal ITR sequence is approximately in the center of the vector genome.

5. The composition of claim 1, wherein the two heterologous nucleotide sequences are inverted complements of each other.

6. The composition of claim 1, wherein the first or the second heterologous nucleotide sequences comprises a coding sequence.

7. The composition of claim 6, wherein the coding sequence is:

(i) a polynucleotide encoding a protein useful in gene therapy to relieve deficiencies caused by missing, defective or sub-optimal levels of a structural protein or enzyme;

(ii) a polynucleotide that is transcribed into an anti-sense molecule;

(iii) a polynucleotide that is transcribed into a decoy that binds a transcription or translation factor, (iv) a polynucleotide that encodes a cellular modulator;

(v) a polynucleotide that can make a recipient cell susceptible to a specific drug;

(vi) a polynucleotide for cancer therapy;

or (vii) a polynucleotide that encodes an antigen or antibody.

8. The composition of claim 6, wherein the coding sequence is the herpes virus thymidine kinase gene, an E1A tumor suppressor gene, or a p53 tumor suppressor gene.

9. The composition of claim 6, wherein the coding sequence encodes a protein or an RNA of therapeutic interest.

10. The composition of claim 6, wherein the coding sequence encodes an antisense RNA or a ribozyme.

11. The composition of claim 6, wherein the coding sequence is operably linked to a promoter sequence.

12. The composition of claim 11, wherein the promoter sequence is (i) an SV40 late promoter, (ii) a baculovirus polyhedron enhancer/promoter element, (iii) a Herpes Simplex Virus thymidine kinase (HSV tk), (iv) an immediate early promoter from cytomegalovirus (CMV), (v) a retroviral promoter including LTR elements, or (vi) a heavy metal ion inducible promoters and a promoter from T7 phage.

13. The composition of claim 11, wherein the coding sequence is further operably linked to an enhancer sequence.

14. The composition of claim 6, wherein the coding sequence is operably linked to a ribosome binding site (RBS).

15. The composition of claim 6, wherein the coding sequence is operably linked to a polyadenylation signal.

16. The composition of claim 1, wherein the AAV capsid is an rAAV2 capsid.

17. The composition of claim 1, further comprising a pharmaceutically acceptable excipient.

18. A method of introducing an rAAV genome into a cell, comprising contacting the cell essentially in the absence of an AAV helper virus with the composition of claim 1 under conditions that allow uptake of the rAAV vector, whereby the rAAV vector is introduced into the cell.

19. A method of expressing a polynucleotide coding sequence in a cell, comprising subjecting the cell to conditions which allow expression of the coding sequence, wherein the coding sequence is introduced into the cell by contacting the cell essentially in the absence of an AAV helper virus with a composition comprising a purified recombinant adeno-associated virus (rAAV) particle, wherein the rAAV particle comprises an AAV capsid and a single-stranded rAAV vector genome, wherein the rAAV vector genome comprises in the 5′

to 3′

direction;

a 5′

AAV inverted terminal repeat (ITR) sequence, a first heterologous nucleotide sequence, an internal AAV ITR sequence, a second heterologous nucleotide sequence, and a 3′

AAV ITR sequence, wherein the first heterologous nucleotide sequence can form intrastrand base pairs with the second nucleotide sequence along most or all of its length, and wherein the first or the second heterologous nucleotide comprises the coding sequence.

20. The method of claim 19, wherein the cell is a mammalian cell.

21. The method of claim 19, wherein the cell is a human cell.

22. The method of claim 19, wherein the composition is essentially free of helper virus.

23. The method of claim 19, wherein the vector genome has a size of about 4.5 kilobase to about 5.2 kilobase.

24. The method of claim 19, wherein the internal ITR sequence is approximately in the center of the vector genome.

25. The method of claim 19, wherein the two heterologous nucleotide sequences are inverted complements of each other.

26. The method of claim 19, wherein the coding sequence is:

(i) a polynucleotide encoding a protein useful in gene therapy to relieve deficiencies caused by missing, defective or sub-optimal levels of a structural protein or enzyme;

(ii) a polynucleotide that is transcribed into an anti-sense molecule;

(iii) a polynucleotide that is transcribed into a decoy that binds a transcription or translation factor, (iv) a polynucleotide that encodes a cellular modulator;

(v) a polynucleotide that can make a recipient cell susceptible to a specific drug;

(vi) a polynucleotide for cancer therapy;

or (vii) a polynucleotide that encodes an antigen or antibody.

27. The composition of claim 19, wherein the coding sequence encodes a protein or an RNA of therapeutic interest.

28. The composition of claim 19, wherein the coding sequence encodes an antisense RNA or a ribozyme.

29. The method of claim 19, wherein the coding sequence is the herpes virus thymidine kinase gene, an E1A tumor suppressor gene, or a p53 tumor suppressor gene.

30. The method of claim 19, wherein the coding sequence is operably linked to a promoter sequence.

31. The method of claim 30, wherein the promoter sequence is (i) an SV40 late promoter, (ii) a baculovirus polyhedron enhancer/promoter element, (iii) a Herpes Simplex Virus thymidine kinase (HSV tk), (iv) an immediate early promoter from cytomegalovirus (CMV), (v) a retroviral promoter including LTR elements, or (vi) a heavy metal ion inducible promoters and a promoter from T7 phage.

32. The method of claim 30, wherein the coding sequence is further operably linked to an enhancer sequence.

33. The method of claim 19, wherein the coding sequence is operably linked to a ribosome binding site (RBS).

34. The method of claim 19, wherein the coding sequence is operably linked to a polyadenylation signal.

35. The method of claim 19, wherein the AAV capsid is an rAAV2 capsid.

36. The method of claim 19, wherein the composition further comprises a pharmaceutically acceptable excipient.